Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Flupirava vs Avigan in Healthy Volunteers
NCT04478448Phase 1Completed
- Sponsor
- Genuine Research Center
- Start
- Aug 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of favipiravir in coronavirus disease 2019 (COVID-19) and influenza (2 arms), sponsored by Genuine Research Center. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to the last measurable concentration and 1 more. Started Aug 2020; status: completed.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT04478448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04478448.